Edwards TAVR Superior to Surveillance in Moderate AS Trial
Edwards Lifesciences said its PROGRESS Trial found TAVR superior to clinical surveillance for moderate aortic stenosis patients with at-risk features.
Story updates
05:40:44 PM UTC
SquawkNews
Edwards Lifesciences TAVR cuts risk of death or heart failure events by 33% in moderate aortic steno
05:40:49 PM UTC
SquawkNews
TAVR de Edwards reduce un 33% el riesgo de muerte o eventos de insuficiencia cardíaca en ensayo de e
Edwards Lifesciences (NYSE:EW) today announced results from the PROGRESS Trial, marking a turning point in the management of moderate aortic stenosis (AS). The trial demonstrated that transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance in the primary composite endpoi…